ANI Pharmaceuticals, Inc. ANIP · Stock Open ANI Pharmaceuticals, Inc. in new tab
ANI Pharmaceuticals, Inc. Analysis (ANIP)
Is ANI Pharmaceuticals, Inc. a good investment? ANI Pharmaceuticals, Inc. (ANIP) is currently trading at 72.96 USD. Market analysts have a consensus price target of 105.78 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 16.12. This valuation is generally in line with the broader market.
Earnings Schedule: ANI Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 6, 2026. The market consensus estimate for Forward EPS is 10.49.
Investor FAQ
Does ANI Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is ANI Pharmaceuticals, Inc.?
ANI Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of 4.59.
Company Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Split Date | Split Ratio to 1 |
|---|---|
| June 3, 2002 | 1:10 |
| June 4, 2012 | 1:6 |
| July 18, 2013 | 1:6 |
Community Discussion